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Abstract
The quality of clinical trials is an essential part of the evidence base for the treatment of headache disorders. In 1991, the
International Headache Society Clinical Trials Standing Committee developed and published the first edition of the
Guidelines for controlled trials of drugs in migraine. Scientific and clinical developments in headache medicine led to
second and third editions in 2000 and 2012, respectively. The current, fourth edition of the Guidelines retains the
structure and much content from previous editions. However, it also incorporates evidence from clinical trials published
after the third edition as well as feedback from meetings with regulators, pharmaceutical and device manufacturers, and
patient associations. Its final form reflects the collective expertise and judgement of the Committee. These updated
recommendations and commentary are intended to meet the Society’s continuing objective of providing a contemporary,
standardized, and evidence-based approach to the conduct and reporting of randomised controlled trials for the acute
treatment of migraine attacks.
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Introduction
In 1991, the Clinical Trials Standing Committee of the
International Headache Society (IHS) published the
ﬁrst edition of the Guidelines for controlled trials of
drugs in migraine (1). Its goal was to improve the qual-
ity of controlled clinical trials in migraine by encoura-
ging the use of scientiﬁcally robust methods in clinical
research. To keep pace with developments in the scien-
tiﬁc and clinical understanding of acute treatment, the
Committee published a second edition of the Guidelines
in 2000 (2) and a third edition in 2012 (3). The com-
mitment to continuous improvement has been recog-
nized; the Guidelines were considered in the 2018
Guidance for industry (4) prepared by the Division of
Neurology Products in the Center for Drug Evaluation
and Research at the Food and Drug Administration
(FDA), and they were adopted by the European
Medicine Agency (EMA) in a 2016 concept paper
that represented an important milestone in its formal
revision of the 2007 Guideline on clinical investigation of
medicinal products for the treatment of migraine (5).
Since the 2012 update, multiple new acute treatments
have been developed, including small molecule calci-
tonin gene-related peptide (CGRP) receptor antagon-
ists, serotonin (5-HT1F) receptor agonists, triptan
reformulations, and neuromodulation approaches.
Accordingly, the Guidelines of the International
Headache Society for controlled trials of acute treatment
of migraine attacks in adults: Fourth edition incorpor-
ates data from clinical trials conducted since the third
edition of the Guidelines was published, as well as feed-
back from meetings with representatives of the FDA
and EMA, pharmaceutical and device manufacturers,
and patient associations. Although the Committee con-
sidered the comments of pharmaceutical and device
manufacturers and members of the IHS on the ﬁrst
draft, the published version is an independent and
unbiased reﬂection of the expertise and consensus
judgement of its members.
The present publication retains the structure of the
third edition (3), with sub-sections for the selection of
subjects, trial design, evaluation of results, statistics,
and special issues, as well as a Toolbox, which provides
readers with an index to content and summary state-
ments for each section. Several challenges in trial design
that were raised in a preliminary statement in the third
edition – speciﬁcally, the timing of acute treatment,
consistency of response, and participants who have
migraine with aura – have been addressed in Sections
1.2.9, 1.2.12, and 2.1, respectively. It is therefore hoped
that this edition of the Guidelines continues the trad-
ition of its predecessors by providing investigators with
a contemporary, standardized, and evidence-based
approach to the conduct and reporting of clinical
trials for the acute treatment of migraine attacks.
1. Clinical trials for the acute treatment
of migraine attacks
1.1. Subject selection
1.1.1. Migraine definition
Recommendation:
Eligible subjects should fulﬁl the diagnostic criteria
for migraine according to the most current version of
the International Classiﬁcation of Headache Disorders
(ICHD) of the IHS (6).
Comments:
Clinical trials of acute treatments for migraine can
include subjects who have migraine without aura,
migraine with aura, and both migraine types, but the
ICHD diagnostic criteria should be fulﬁlled to avoid
population heterogeneity. In trials focusing on the
acute treatment of migraine with aura, subjects with
both migraine types can be included, as aura symptoms
are recognizable, the attack types are distinguishable,
and most people who have migraine with aura also
have attacks of migraine without aura (7). (Refer to
Section 2.1 for more information about migraine with
aura.) In trials enrolling participants with a history of
both types of attacks, the type of the treated attack
should be classiﬁed according to ICHD criteria based
on the clinical features captured in a diary. Note that
this requirement may be impractical when subjects are
instructed to treat early, because early treatment of
migraine can modify the clinical features of an attack
and thereby prevent analysis by type (refer to Section
2.2 for more information about early intervention
trials). In some instances, after eﬃcacy and safety
have been demonstrated in subjects with conﬁrmed
diagnoses of migraine without aura and migraine with
aura, trials targeting subjects with probable migraine –
migraine-like attacks missing one of the features
required to fulﬁl all criteria for a type or subtype of
migraine (6) – may be appropriate.
1.1.2. Other primary headaches
Recommendations:
1.1.2.1. Individuals satisfying criteria for chronic
migraine or with a history of chronic migraine in
the last 12 months should be excluded from pivotal
eﬃcacy trials for the acute treatment of migraine.
In subsequent trials, exploration of the beneﬁts of
new acute treatments in subjects with chronic migraine
is needed.
1.1.2.2. Subjects with other concomitant primary
headache types (e.g. tension-type headache) are allowed
if attacks are infrequent (i.e. present on an average
of< 1 day/month and< 12 days/year) (6) and can be
diﬀerentiated from migraine based on the quality of
pain and associated symptoms.
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Comments:
Individuals with chronic migraine are excluded from
the initial clinical trials of acute treatment because they
may complicate analyses of eﬃcacy in undiﬀerentiated
populations (refer to (8) for guidance about trials eval-
uating preventive treatments in adults with chronic
migraine). Subjects with migraine may have other pri-
mary headache types, including tension-type headache
(2). Those experiencing primary headaches that cannot
be distinguished from ICHD-deﬁned migraine without
aura (6) should be excluded.
1.1.3. Secondary headaches
Recommendation:
Individuals with secondary headaches, including
medication-overuse headache, should be excluded.
Comments:
Excessive use of acute medications for migraine does
not necessarily lead to medication-overuse headache,
and some individuals may fulﬁl IHS criteria for overuse
of acute medications without suﬀering from a chronic
pattern of headache. The secondary headache exclusion
also applies to these subjects.
1.1.4. Frequency of attacks
Recommendations:
1.1.4.1. Attacks of migraine should occur two to
eight times per month.
1.1.4.2. The frequency of other headaches (including
non-target) must be no greater than 1 day per month.
1.1.4.3. There should be at least 48 hours of freedom
from headache between attacks of migraine under study.
1.1.4.4. Subjects should experience fewer than 15
headache days per month.
Comments:
A minimum of two attacks per month is recommended.
The maximum frequency of eight attacks per month
reduces the probability that those with incipient medica-
tion overuse, medication-overuse headache, or chronic
migraine will be included in the trial. Allowing 48 hours
of freedom from headache between migraine attacks per-
mits clear identiﬁcation of individual attacks and distinc-
tion from relapse, and it avoids the use of multiple
treatments for a single prolonged attack. The evaluation
of three to ﬁve consecutive attacks provides information
on consistency of response and may attenuate the placebo
eﬀect on the ﬁrst attack (refer to Section 1.2.12 for more
information about consistency of response).
1.1.5. Duration of migraine
Recommendation:
Migraine should be present for at least 1 year prior
to inclusion in a clinical trial.
Comments:
Because there are no objective signs or biomarkers
for the diagnosis of migraine, and the 1-year require-
ment increases the speciﬁcity of the diagnostic criteria,
a minimum course of 1 year is advised to exclude
people with headache types that may mimic migraine.
The history may be based on subject recall or physician
evaluation of medical records. At least ﬁve prior
attacks of migraine without aura or two prior attacks
of migraine with aura are required for diagnoses using
ICHD criteria (6).
1.1.6. Age at onset
Recommendation:
The age at onset of migraine should be less than 50
years.
Comments:
Few adults will be excluded by this criterion, as
migraine beginning after the age of 50 years is rare,
and the prevalence of secondary headaches or organic
diseases mimicking migraine increases after age 50. The
inclusion of subjects with onset of migraine after 50
years of age can be considered in phase IV trials, as
long as the migraine diagnosis is well established by
ICHD criteria, and secondary headaches have been
ruled out.
1.1.7. Age at entry
Recommendation:
Adult subjects participating in clinical trials should
be between 18 and 65 years of age at entry.
Comments:
Only people who are at least 18 years old can pro-
vide informed consent. The inclusion of subjects older
than 65 years is encouraged in post-marketing surveil-
lance studies. After age 65, those with migraine are
more likely to have (and be taking medications for)
coexistent conditions than a younger population,
which can confound assessments of safety and drug-
drug interactions. Adverse health-related outcomes
due to coexistent disease may be diﬃcult to separate
from a complication of the treatment under
investigation.
1.1.8. Sex
Recommendation:
1.1.8.1. Males and females with migraine are eligible
to participate in clinical trials of acute migraine
medications.
Comments:
Migraine is at least three times more prevalent in
females than in males (9–12). Special caution should
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be taken to avoid enrolling women who may be preg-
nant or lactating, unless they are the target of the trial.
Partners of fertile-age women should practice eﬀective
contraception (refer to Section 2.3 for information
about menstrual migraine).
1.1.9. Concomitant drug use
Recommendations:
1.1.9.1. Therapies not for migraine. Trials allowing
participants to treat conditions other than migraine
should pre-specify the permitted uses of concomitant
therapies (i.e. open or restricted). The use of contracep-
tive medication should also be pre-speciﬁed. In phase II
clinical trials, subjects should not be allowed to treat
conditions other than migraine unless pharmacokinetic
(PK) and pharmacodynamic (PD) analyses have clearly
shown a lack of interactions between the intervention
being assessed for migraine and the concomitant ther-
apy. In later development trials (i.e. phase III and IV),
the treatment of concomitant and comorbid conditions
may be speciﬁcally permitted with due precautions.
1.1.9.2. Acute migraine treatment. Investigational
treatments should not be administered until at least
48 hours after the use of other acute treatments for
migraine, including over-the-counter (OTC) drugs, pre-
scription medications, and medical devices.
1.1.9.3. Preventive migraine treatment. If considered
exclusionary, the withdrawal of migraine preventive
treatment should be completed and the last dose
taken at least 1 month before enrolment. For partici-
pants taking preventive drugs with a long half-life, at
least ﬁve half-lives should elapse before enrolment.
When the protocol permits migraine preventive drugs,
subjects should be on a stable dose of no more than one
preventive agent for at least 2 months before enrolment
to ensure a stable baseline.
1.1.9.4. Antipsychotics and antidepressants. People
who have used antipsychotics on a regular basis
during the 3 months prior to consideration for enrol-
ment should be excluded from phase II clinical trials.
Individuals co-medicating with antidepressants may be
considered for inclusion.
Comments:
Evaluating the potential for interactions is an
important aspect of development prior to approval
and marketing, especially in the case of small mol-
ecules. The absence of a clear understanding of PK
and PD proﬁles and possible drug-drug and drug-
device interactions can obscure the interpretation of
treatment eﬀects and adverse events (AEs). Persons
with a substance use disorder, as deﬁned by the
Diagnostic and statistical manual of mental disorders,
ﬁfth edition (13), should be excluded from clinical
trials. Individuals using cannabinoids to treat migraine
attacks should also be excluded because the possible
eﬀects on pain can confound outcomes. People
known to be generally resistant to acute anti-migraine
drugs may bias results if they are overrepresented in a
trial population. However, because factors such as
inadequate dosing, treating late in the course of an
attack, inadequate trial, or frequent relapse may be
perceived as drug failure or treatment resistance, inves-
tigators should establish the true nature of prior treat-
ment failures before excluding those who report them
from participation.
1.2. Trial design
1.2.1. Blinding
Recommendation:
Phase II and III eﬃcacy trials of therapies for the
acute treatment of migraine should use a double-blind
design.
Comments:
Drugs intended for the acute treatment of migraine
attacks can only be reliably evaluated in randomized,
double-blind, placebo-controlled trials. Blinding may
not be required in long-term safety trials and natural-
istic trials.
1.2.2. Placebo control
Recommendations:
1.2.2.1. Interventions under evaluation for the acute
treatment of migraine should be compared with
placebo.
1.2.2.2. When two presumably active treatments are
compared, a placebo control should be included for
assay sensitivity.
Comments:
The placebo eﬀect is a genuine psychobiological phe-
nomenon that aﬀects the results of clinical trials across
diﬀerent disease states (14). In trials for the acute treat-
ment of migraine placebo response varies widely, from
6% to 56% for headache relief (15) and from 6% to
25% for pain freedom (16,17). This variability makes it
diﬃcult to interpret the results of active comparator
trials that do not include placebo. Trials using historical
controls or active comparators lack assay sensitivity
and require large sample sizes to provide the narrow
conﬁdence intervals (CIs) needed to ensure that new
drugs are not inferior to controls (18).
In the past, modiﬁed designs (e.g. exclusion of pla-
cebo responders or sequential parallel designs) to
reduce placebo response have proved poorly eﬀective.
Nonetheless, particular care should be dedicated to
identify and mitigate placebo response risks as much
as possible.
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1.2.3. Design types
Recommendations:
1.2.3.1. Although both parallel-group and crossover
designs may be used, parallel-group designs are preferred.
1.2.3.2. Limited to phase II trials, group-sequential,
adaptive treatment, and dose-deﬁning designs may be
appropriate.
Comments:
The parallel-group design has the advantage of sim-
plicity. Parallel-group trials have successfully demon-
strated both superiority and similarity among
treatments. Multiple-attack, parallel-group designs
can be used to assess intra-individual consistency of
response, although carry-over eﬀects and intra-indivi-
dual correlation must be taken into account (refer to
Section 1.2.12 for information about consistency of
response). With crossover trial designs, period and
carry-over eﬀects may occur, and complexities may be
introduced if the tested treatment has notable side
eﬀects. Crossover designs can also be used in multi-
ple-attack trials to estimate intra-individual consistency
of response with placebo-control groups (19). In add-
ition, crossover designs allow for the assessment of
acute treatment preferences. Subjects who have taken
more than one treatment can be asked which treatment
they would prefer to take again. Reponses to this ques-
tion reﬂect subjects’ net assessment of beneﬁts and tol-
erability (20). Given the popularity of social media,
participants in crossover trials should be instructed to
refrain from posting about the trial.
Non-traditional clinical trial designs include step-wise,
adaptive, enriched designs and futility trials. Adaptive
designs allow for the modiﬁcation of aspects of a trial
(e.g. dosing) while in progress without undermining its
scientiﬁc validity or integrity. For phase II evaluations
of optimal dosing, randomised group-sequential, adaptive
treatment, dose-deﬁning, proof-of-concept (21–23) and
two-stage, adaptive, dose-ranging (24) designs are appro-
priate. The major advantage of these non-traditional
designs is that they allow evaluation of the lowest eﬀective
dose and highest tolerated dose over a wide dose range in
relatively few subjects. The chosen dose(s) can then be
conﬁrmed as optimal in phase III clinical trials.
1.2.4. Randomization
Recommendation:
Subjects enrolled in parallel-group and crossover
trials should be randomized at entry to the trial,
except when considering adaptive randomization.
Comments:
True randomization is crucial to avoid bias and,
in large trials, to contribute to group matching.
Block randomization using varying block sizes (e.g.
blocks sizes of two, four, six, etc.) may be helpful in
preventing participants from guessing treatment
assignments.
1.2.5. Stratification
Recommendations:
1.2.5.1. There is usually no need for stratiﬁcation in
acute treatment trials.
1.2.5.2. Stratiﬁcation may be considered when an
imbalance between the treatment groups or an import-
ant factor may inﬂuence the results of a trial.
Comments:
Randomization alone may not ensure full compar-
ability between subjects in diﬀerent treatment groups,
especially in smaller trials, and stratiﬁed randomization
is sometimes used to circumvent potential imbalances.
The EMA recommends that stratiﬁcation variables
usually be included as covariates in primary analyses,
regardless of their prognostic value (25). In controlled
trials for migraine, the use of stratiﬁcation by prognos-
tic factors should be limited to a few variables and only
to those that have historically demonstrated eﬀects on
primary eﬃcacy endpoint(s). Stratiﬁcation variables
that have been used in acute treatment trials include
age, body weight, headache intensity at baseline,
migraine type (i.e. with or without aura), menstrual
versus non-menstrual attacks, and concomitant pre-
ventive treatment (26–28). Given the preponderance
of females with migraine, sex may also be used as a
stratiﬁcation factor to control for imbalances in treat-
ment groups.
1.2.6. Intention to treat
Recommendations:
1.2.6.1. Randomized controlled trials of acute treat-
ments for migraine should follow the principle of inten-
tion to treat (ITT), which implies that analyses should
include all randomised subjects in the groups to which
they were randomly assigned, regardless of treatment
received.
1.2.6.2. The full analysis set may be modiﬁed to
exclude subjects from the analysis if no treatment was
taken or if no data points after treatment were rec-
orded. A plan should be provided prospectively as to
how participants missing the 2-hour endpoint or who
treat but do not record data will be handled. Those who
treat but do not record data should probably be
counted as failures, and those who use rescue medica-
tion before the 2-hour time assessment should be
counted as failures.
Comments:
The ITT principle encourages, where reasonable,
the inclusion of subjects who withdrew, were lost to
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follow-up, or did not fully adhere to trial protocol (29).
The ITT principle should be adhered to when the pri-
mary outcome is a variable that measures a change
from baseline to any post-dose time point or to the
end of the trial. When the primary outcome is deﬁned
as a rate of change, and the analysis will therefore imply
a slope or rate of calculation, only subjects who have
received at least one dose and recorded at least one data
point should be included.
1.2.7. Dose-response curves and dosage
Recommendations:
1.2.7.1. Dose-response curves should be deﬁned
clearly in early (phase I and II) randomized, clinical
trials of new chemical entities for the acute treatment
of migraine.
1.2.7.2. Eﬃcacy- and tolerability-based minimum
eﬀective and optimal doses should be determined.
1.2.7.3. Eﬀective doses of a well-established or stand-
ard drug should be utilized in comparative clinical
trials, unless clinically inappropriate, in which case a
clear justiﬁcation for the particular dose selection
should be given.
Comments:
New acute treatments for migraine should be tested
against a standard comparator with established
dose-response curves and optimal eﬃcacy- and toler-
ability-based doses, such as rizatriptan, sumatriptan,
or zolmitriptan (30–34); the CGRP receptor antagon-
ists (i.e. gepants) ubrogepant and rimegepant (23,35);
or the 5-HT1F receptor agonist lasmiditan (22).
The accepted optimal therapeutic dose of the com-
parator should be used.
1.2.8. Route of administration
Recommendations:
1.2.8.1. When pre-clinical and PK data demonstrate
an acceptable PK proﬁle in humans (i.e. good oral bio-
availability and rapid oral absorption), oral administra-
tion of the test treatment is recommended because the
oral route is preferred by most people with migraine (36).
1.2.8.2. Alternative routes of administration, includ-
ing parenteral, inhalational, buccal, intranasal, and
rectal, can be utilized as circumstances dictate (e.g.
severe nausea, status migrainosus).
Comments:
Gastric absorption of orally-administered medica-
tions can be delayed during migraine attacks (37–40).
In early phase I or II trials, therefore, it is advisable to
establish the intra- and interictal PK proﬁle of oral
treatments utilizing a crossover design in order to
gauge dose selection in later eﬃcacy trials.
1.2.9. Timing of administration
Recommendations:
1.2.9.1. The timing of acute treatment should be
deﬁned in the trial protocol.
1.2.9.2. Usually, participants are instructed to treat
when migraine headache pain is of at least moderate
intensity, but alternatives include treating as soon as
possible after headache onset, treating when pain inten-
sity is mild, and treating when pain intensity is severe.
1.2.9.3. The timing of acute treatment must be con-
sistent with the objectives of the trial.
1.2.9.4. Subjects should record the time and pain
intensity at the time of treatment in the trial diary.
Comments:
The head pain of migraine frequently begins with
mild intensity, progressively increases with variable
speed to a peak, and is followed by resolution; head-
ache pain can also ﬂuctuate spontaneously during a
migraine attack (41). These characteristics can pose
challenges regarding the timing of treatment (e.g.
early or when the attack is fully developed) and the
evaluation of trial results. For example, healthcare pro-
viders typically recommend treating early in the course
of a migraine attack, while pain intensity is mild,
because it can enhance eﬃcacy (18,42,43). At the begin-
ning of an attack, however, migraine without aura can
be diﬃcult to distinguish from non-migraine headaches.
Thus, subjects in migraine clinical trials who are
instructed to treat as soon as possible (i.e. at the ﬁrst
sign of migraine) may mistakenly treat other headache
types. The potential for confusion is mitigated when
attacks are allowed to fully develop. Having subjects
wait until pain intensity is moderate or severe before
treating increases the speciﬁcity of migraine diagnoses.
Yet because this strategy conﬂicts with common clinical
advice about early treatment, it is essential that partici-
pants in clinical trials receive clear instruction
about when to use acute treatment. In later stages of
development, depending on the speciﬁc objectives of
the program, trials evaluating early intervention and
treatment when headache pain intensity is severe (e.g.
for early morning migraine (44)) are encouraged when
investigating the eﬃcacy, safety, and tolerability of new
treatments.
1.2.10. Number of attacks treated
Recommendations:
1.2.10.1. Determining the eﬀect of an acute treat-
ment on the ﬁrst migraine attack should be the primary
objective. The attack to be considered should be clearly
speciﬁed in the protocol.
1.2.10.2. If multiple attacks are treated, the ﬁrst trea-
ted attack or the attack that will be considered for
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assessing the primary objective can be randomly
selected.
Comments:
In most clinical trials of acute treatment, the ﬁrst
treated attack will be used in the evaluation of eﬃcacy.
Refer to Section 1.2.12 for information about multiple-
attack trials addressing consistency of response as a
primary objective (45–48).
1.2.11. Rescue medication
Recommendations:
1.2.11.1. The use of rescue medication should be
allowed at any time after the ﬁrst primary eﬃcacy
time point, typically 2 hours after the initial adminis-
tration of treatment.
1.2.11.2. Use of rescue medication before the 2-hour
endpoint should be considered a treatment failure
unless an earlier time point for rescue was pre-speciﬁed
in the trial protocol.
Comments:
The time interval to using rescue medication can be
reduced when the primary eﬃcacy time point is before 2
hours, which is often the case in assessments of paren-
teral drugs or trials involving paediatric subjects. Little
can be learned from delaying rescue medications
beyond the primary eﬃcacy time point. Furthermore,
delays may unduly discomfort subjects and prolong the
attack and associated disability, which are ethically
unacceptable. Rescue medication can be taken before
the time of the primary endpoint if subjects require it,
but such use should be recorded as a treatment failure.
1.2.12. Consistency of response
Recommendations:
1.2.12.1. Intra-individual consistency of response
may be evaluated over multiple attacks in double-
blind, placebo-controlled trials.
1.2.12.2. Response to at least four attacks should be
assessed, and at least one of the four attacks should be
treated with placebo in a randomized fashion.
Comments:
Population-level consistency of response refers to the
proportion of treated subjects who achieve a trial end-
point for the ﬁrst, second, third, or nth treated attack.
This is best assessed in randomized controlled trials
evaluating multiple attacks ( 4) using any of the fol-
lowing three designs. In the ﬁrst design, all subjects use
active treatment for at least three attacks, with placebo
in one additional attack, in a randomized order. The
second design administers the active treatment for all
attacks in most subjects, while a subset uses both active
treatment and placebo in a randomized manner for at
least four attacks. The third design uses a combined
approach, with an initial 1-month double-blind phase
(subjects use active treatment or placebo for the ﬁrst
attack) followed by a 1- or 2-month open-label phase,
during which subjects treat at least three attacks with
the active intervention.
Testing the eﬀect of an acute treatment on several
migraine attacks may increase the discriminative power
for eﬃcacy when outcome measures are averaged
across multiple attacks for each subject, provided that
all analysed subjects treat the same number of attacks.
Using a generalized estimating equation or random-
eﬀects modelling, all treated attacks can be used as a
basis for comparison (49,50). Generalized estimating
equations control for intra-individual correlation,
whereas random-eﬀects models treat each individual
as a random eﬀect. However, the increase in analytic
power can be counterbalanced by a decrease in the
number of subjects completing the trial. Relative to
single-attack trials, multiple attack trials have higher
dropout rates and may introduce an unmanageable
bias if dropouts are related to tolerability issues or
lack of eﬃcacy (51,52). Furthermore, repeated intake
of placebo when a standard treatment is available raises
ethical issues.
Assessing intra-individual and population-level con-
sistency of response has been diﬃcult in long-term
safety trials because they rarely include a placebo con-
trol and often introduce selection bias when responders
from an eﬃcacy trial are carried over (53). Long-term
trials should be used to evaluate the development of
tolerance (tachyphylaxis).
1.3. Evaluation of results
1.3.1. Attack report form (diary)
Recommendation:
An easy-to-use electronic diary that captures prede-
ﬁned endpoints should be used. Investigator-initiated
trials may use paper diaries (54).
Comments:
Headache characteristics and response to treatment
are best recorded by means of electronic diaries with
time-stamp capabilities. Data for the index attack and
the 2-hour time point should be entered in real time.
Adverse events may be collected in the diary or during
follow-up visits. Serious AEs need to be reported within
24 hours. In settings where electronic diaries are not
available (e.g. investigator-initiated trials), paper dia-
ries may be used.
With diaries, the quantity and quality of collected
data tend to be inversely proportional. Complicated
report forms with detailed description of symptoms
may be diﬃcult for subjects to ﬁll out during attacks.
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Some trials have been successful using algorithms to
ensure that the treated attack is a migraine (55,56).
Familiarization with data capture on the trial diary
is important. Subjects can complete the diary report for
an attack whilst treating with their usual medication
prior to entering the trial, and the data are reviewed
at the trial site. Subjects can also be asked to complete
the diary at the randomization visit by recalling events
of their most recent attack. The latter procedure is pref-
erable because it minimizes delays in trial participation.
1.3.2. Primary endpoint: Pain freedom at 2 hours
Recommendation:
1.3.2.1. The percentage of subjects who become pain
free at 2 hours after treatment, before the use of any
rescue medication, should be the primary measure of
eﬃcacy.
Comments:
Freedom from pain before the use of rescue medica-
tion is simple, clinically relevant, reﬂects patients’
expectations (57,58), and is independent of the con-
founding eﬀects of other therapies (e.g. rescue medica-
tion). With respect to the 2-hour time point, it may be
argued that because some acute treatments have a slow
time to maximum or time to eﬀective plasma concen-
tration, an expectation of pain freedom within 2 hours
of treatment is unrealistic. This position runs counter to
the principles of Good Clinical Practice (59), which give
the highest consideration to subject wellbeing; partici-
pants in clinical trials should not be subjected to undue
harm, and the use of eﬀective rescue therapies should
not be delayed beyond 2 hours. Pain freedom at times
before 2 hours should be considered as an endpoint in
trials of non-oral treatments (e.g. intravenous, intra-
muscular, subcutaneous, intranasal).
1.3.3. Co-primary endpoint: Absence of the most bothersome
symptom
Recommendation:
Absence of the most bothersome migraine-asso-
ciated symptom at 2 hours after treatment may be
used as a co-primary endpoint.
Comments:
In addition to headache pain, migraine attacks are
characterized by a number of associated symptoms,
including nausea, vomiting, photophobia, and phono-
phobia (6). To align outcomes in controlled trials with
symptom(s) of clinical signiﬁcance, it is important to
measure the eﬀects of an acute treatment on all
these features. For regulatory purposes, the FDA
recommends that eﬃcacy analyses in acute trials use
as co-primary endpoints the proportion of subjects
with no headache pain at 2 hours after treatment and
the proportion of subjects with absence of the most
bothersome associated symptom (MBS) at 2 hours
after treatment (4). The use of the MBS as a co-primary
endpoint with pain freedom is an alternative to request-
ing demonstration of a positive treatment eﬀect on all
three migraine associated symptoms; it requires larger
sample sizes due to the need to consider the frequency
of the symptoms. The MBS endpoint should be selected
just prior to study drug administration and measured
on a binary scale (present or absent) using either of two
suggested methods. One method allows subjects to
select the MBS prior to randomization and then treat
only an attack that occurs with the pre-speciﬁed MBS.
The other is to use a time-locked recording device (e.g.
an electronic diary) and have subjects record their MBS
at the onset of the treated attack and then record the
eﬀect on the MBS at 2 hours. The trial protocol should
specify which of these approaches will be used by all
subjects in a clinical trial.
It should be noted that an eﬀect on associated symp-
toms is very diﬃcult to achieve in trials investigating
early treatment, when headache is mild and associated
symptoms may not have appeared yet. Moreover, mea-
suring the elimination of an associated symptom
that was not present at the time treatment was taken,
especially for less common symptoms (e.g. nausea),
substantially increases the required sample size and
number of subjects that must be exposed. An alterna-
tive approach would be to record the elimination of all
associated symptoms at 2 hours after treatment.
1.3.4. Secondary endpoints
1.3.4.1. Relapse
Recommendations:
1.3.4.1.1. Relapse is a secondary treatment failure
that is deﬁned as the occurrence of headache of any
severity within 48 hours of the administration of an
investigational treatment among subjects who were
pain free 2 hours after the investigational treatment
was administered.
1.3.4.1.2. A time interval of 24 hours may be con-
sidered if the treatment under investigation has a short
half-life.
1.3.4.1.3. Relapse rates should not be compared
across trials, and it is recommended that investigators
evaluate the diﬀerential rates of relapse in comparative
trials only when primary eﬃcacy rates are similar (60).
Comments:
Relapse is a major problem with all eﬀective
migraine treatments (61,62), and its incidence should
be recorded in all trials. Relapse was previously
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known as ‘‘recurrence’’ and deﬁned as initially obtain-
ing pain freedom (refer to Section 1.3.2) or headache
relief (refer to Section 1.3.4.5) and subsequently experi-
encing a moderate or severe headache or using rescue
medication (even for mild headache pain) from the time
point of primary eﬃcacy and up to 48 hours. The
reported incidence of relapse under the older deﬁnition
varied considerably (e.g. from 6% to 50% with oral
triptans (63,64)), and it is expected that estimates will
stabilize when analyses are based on the new deﬁnition.
1.3.4.2. Sustained pain freedom
Recommendations:
1.3.4.2.1. Sustained pain freedom is deﬁned as the
percentage of subjects who are pain free at 2 hours
with no use of rescue medication or relapse within 24
or 48 hours of the initial treatment.
1.3.4.2.2. Sustained pain free is a recommended sec-
ondary endpoint, and it is the primary endpoint in early
intervention trials.
Comments:
Sustained pain freedom is an important measure of
migraine treatment response. By integrating initial
response, use of rescue medication, and relapse
(60,61), the sustained pain-free rate is a more scientif-
ically robust outcome measure than the relapse rate
alone. It is therefore recommended over relapse as an
endpoint in comparative trials (65). Investigators
should be aware that the clinical success of acute treat-
ment may be underestimated when using this narrowly-
deﬁned eﬃcacy outcome measure, but it has been
useful in comparing triptans (66) and can be useful
for non-triptan comparisons. Sustained pain freedom
can also be helpful in trials evaluating the use of
acute treatment in subjects with mild pain (e.g. early
intervention trials).
Sustained relief is a composite eﬃcacy outcome
measure based on concepts similar to those of sustained
pain-free. It is deﬁned as headache relief (not pain free-
dom) and absence of relapse or use of rescue medica-
tion after the initial response (67). Sustained relief is not
recommended as a secondary eﬃcacy outcome
measure.
1.3.4.3. Total freedom from migraine
Recommendations:
1.3.4.3.1. The absence of pain, nausea, vomiting,
photophobia, and phonophobia at the primary eﬃcacy
time point (i.e. 2 hours after treatment in most
acute trials) is deﬁned as total freedom from migraine.
This endpoint can be used as a secondary eﬃcacy
measure.
1.3.4.3.2. Freedom from headache and any migraine-
associated symptoms may also be considered.
Comments:
Total freedom from migraine is a combined eﬃcacy
measure that addresses pain and associated symptoms.
Statistically, it is up to four times more powerful than
analyses using four separate co-primary endpoints, as
the majority of people with migraine do not exhibit all
associated symptoms, and because these endpoints are
not necessarily independent (68). In a post-hoc analysis
based on pooled data from the rizatriptan clinical drug
development program, rates of total freedom from
migraine were 35% for rizatriptan and 8% for placebo
(68). Rates of total freedom from migraine tend to be
discouragingly low and often underestimate the beneﬁts
of eﬀective acute treatments.
1.3.4.4. Headache intensity
Recommendations:
1.3.4.4.1. Subjects should note the intensity of head-
ache immediately before the ﬁrst use of the acute treat-
ment being evaluated and at each subsequent pre-
speciﬁed time point.
1.3.4.4.2. Headache intensity should be measured
on a 4-point scale where 0¼ no headache; 1¼mild
headache; 2¼moderate headache; 3¼ severe headache.
Alternatively, a 100-mm Visual Analogue Scale
(VAS) or an 11-point numerical rating scale (NRS)
can be used.
1.3.4.4.3. Collecting data about headache intensity at
the primary eﬃcacy time point (e.g. 2 hours) and before
any rescue medication use is critical for the analysis of
the pain-free primary eﬃcacy outcome measure.
1.3.4.4.4. Headache intensity should be measured at
the time of treatment, every 30 minutes until 2 hours
after treatment; hourly until 4 hours after treatment;
at 12, 24, and 48 hours after treatment; and at the
time of relapse.
1.3.4.4.5. If the time course of treatment eﬀect on
headache intensity has been established in earlier
trials, fewer time points can be used (i.e. 1, 2, and 4
hours after treatment).
Comments:
The ordinal 4-point scale is the preferred instrument
for measuring headache intensity. It is easy to under-
stand and use, and it can be employed in association
with the VAS or 11-point NRS (54). The VAS has
shown a very high level of concordance with the cat-
egorical scale (69), and the NRS is responsive and easy-
to-use in everyday practice; evidence from trials in
other painful conditions suggests that the NRS may
oﬀer a higher discriminatory capability than a categor-
ical scale for pain exacerbations (70). Trials evaluating
the use of acute treatment for mild pain may use sus-
tained pain free as a primary outcome measure, with
pain intensity diﬀerence (PID) and sum of pain
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intensity diﬀerences (SPID) considered as secondary
endpoints. Used widely in non-headache pain trials
(71) and rarely in trials of acute migraine treatment
(72,73), PID and SPID have been shown to yield
similar results to a 2-hour pain-free analysis (74), the
4-point scale, and the VAS (75–77).)
1.3.4.5. Headache relief
Recommendations:
1.3.4.5.1. Headache relief (45), deﬁned as the
decrease in headache pain from moderate or severe at
baseline to mild or none at 2 hours after treatment and
before taking any rescue medication (refer to Section
1.2.11), should be used as a secondary eﬃcacy measure.
1.3.4.5.2. A time point before 2 hours after treatment
can be used when testing parenteral treatments.
Comments:
Headache relief should be used as an outcome meas-
ure, but only as a secondary endpoint and mainly to
facilitate comparison of the results of new clinical trials
with those of previous programmes (30–32,61,74–78).
Since headache relief is associated with relief of disabil-
ity, it can be used in clinical trials as a proxy for pain
improvement and restoration of function. Headache
relief is also useful for comprehensive cost of treatment
analyses.
In older acute migraine clinical trials, headache relief
at 2 hours after treatment was used extensively as a
primary eﬃcacy outcome (30,31,45,58,79) based on
the suggestion that patients may consider an acute
treatment eﬀective while residual headache pain persists
(45). The validity of this argument has been challenged
by evidence showing that patients do not believe a
reduction in headache pain from moderate to mild con-
stitutes success (80) and expect acute treatment to pro-
vide freedom from pain (57,58). In addition, the
headache relief endpoint assumes that the magnitude
of change from severe pain to no pain is clinically
equivalent to the change from moderate pain to mild
pain, which is not the case (81). Finally, the verbal
rating of pain intensity as 0¼ none, 1¼mild, 2¼mod-
erate, and 3¼ severe assumes it is an interval variable in
the absence of clinical validation.
1.3.4.6. Time to meaningful relief
Recommendation:
Time to meaningful relief can be used as a secondary
eﬃcacy measure.
Comments:
Time to meaningful relief is most often assessed by
subjects using electronic diaries with time-stamp cap-
abilities, which have largely replaced the use of stop-
watches (73,75). The time-stamped information
improves the precision of time estimates relative to
the ﬁxed-interval assessments once commonly used in
migraine trials by providing data about treatment
response over a clinically relevant period of time
instead of at pre-speciﬁed time points (e.g. 1, 2, or 4
hours after treatment). Time stamping also allows diary
entries for time to meaningful relief to be analysed by
powerful statistical methods, such as survival analysis
(82,83), that are superior to analyses based on ﬁxed
intervals.
1.3.4.7. Time to pain freedom
Recommendations:
1.3.4.7.1. Speed of onset of therapeutic eﬀect can be
evaluated using a survival analysis of pain freedom at
time points earlier than 2 hours after treatment.
1.3.4.7.2. Time to pain freedom is a recommended
secondary eﬃcacy outcome measure.
Comments:
Time to pain freedom is a more exact measure than
time to meaningful relief. Ratings of headache intensity
at pre-deﬁned time points before 2 hours (e.g. at 10- to
15-minute intervals) can be used to analyse the speed of
onset of treatment response. Investigators should be
aware that additional data recordings can complicate
headache diaries and potentially lead to missing data.
Time-to-event analysis is the most appropriate stat-
istical method to assess speed of onset of therapeutic
eﬀect, using no headache when pain freedom is the out-
come and mild or no headache when headache relief is
the outcome. The diﬀerence between two treatments
should be expressed as a percentage, and because
p-value calculations alone can be misleading, 95% CIs
should be given in order to better inform readers about
the signiﬁcance of the diﬀerence. Time-to-headache
relief analyses have been used in previous trials
(77,78,84), but early response rates were relatively
small. Subcutaneous sumatriptan is an exception
(85,86).
1.3.4.8. Duration of attacks
Recommendation:
Duration of attacks should not be used as an eﬃcacy
measure.
Comments:
The duration of a migraine attack can be inﬂuenced
by the eﬀect of treatment, as well as by physiological
factors (e.g. sleep) and external variables (e.g. use of
rescue medication beyond 2 hours). Since these vari-
ables cannot be controlled for in a clinical trial, they
prevent an accurate and scientiﬁcally sound interpret-
ation of the independent eﬀect of an investigational
intervention. The robustness of the pain freedom and
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sustained pain freedom outcome measures mitigates the
need for attack duration as an eﬃcacy measure.
1.3.4.9. Rescue medication
Recommendations:
1.3.4.9.1. The percentage of patients taking rescue
medication 2 hours after intake of the test treatment
can be used as a secondary eﬃcacy measure.
1.3.4.9.2. The assessment of rescue use medication
can be earlier if the primary outcome measure is speci-
ﬁed at a time earlier than 2 hours after treatment.
Comments:
Theoretically, use of rescue medication at the primary
eﬃcacy time point reﬂects a judgement of the ineﬃcacy
of the test treatment, but subjects in clinical trials may
use rescue medication for conditions other than head-
ache (e.g. anxiety, sleep, or associated symptoms). Rates
of rescue medication usage have been found to be as
sensitive as 2-hour pain-free rates in some trials
(86–88), but not in others (89). The use of rescue medi-
cation should not be postponed beyond 2 hours after
treatment; its use may be permitted at 1 hour after treat-
ment in paediatric trials and in trials where the primary
time point for eﬃcacy is at 1 hour after treatment.
1.3.4.10. Global evaluation
Recommendations:
1.3.4.10.1. Subjects’ global impression of acute treat-
ment eﬀect can be used as a secondary outcome meas-
ure. Eﬃcacy and tolerability should be evaluated
separately.
1.3.4.10.2. A simple Likert-type verbal scale is rec-
ommended (e.g. very poor, poor, no opinion, good,
very good).
1.3.4.10.3. Investigator’s impression of treatment
eﬀect should not be used.
Comments:
Subject’s global impression of change from baseline —
the global impression of an investigational treatment’s
eﬀect — is one of the most clinically relevant outcomes
because it is a composite assessment of treatment eﬀects
on headache, associated symptoms, and AEs (tolerabil-
ity). Several scales, including the Patient Global
Impression of Change (PGI-C), have been used to
assess global impression of change in migraine trials
(22,90–92). Global impression of change is recommended
for use in phase III and IV trials, as well as for clinical
trials comparing two or more active treatments.
1.3.4.11. Global impact (functional disability and quality
of life). Functional disability and health-related quality
of life (HRQoL) are important secondary global meas-
ures that account for the impact of headache and
associated symptoms, as well as any adverse eﬀects of
treatment.
Recommendation:
1.3.4.11.1. Subjects should assess functional disability
just before and up to 2 hours after the administration of
acute treatment, before the use of rescue medication,
using a simple verbal, numerical scale. The following
question is recommended: ‘‘How well can you function
right now?’’ Response options should be: 0¼ no disabil-
ity (i.e. able to function normally); 1¼mild disability
(i.e. able to perform all activities of daily living but
with some diﬃculty); 2¼moderate disability (i.e.
unable to perform certain activities of daily living);
3¼ severe disability (i.e. unable to perform most to all
activities of daily living or requiring bed rest).
Comments:
Disability can be deﬁned as a decrement in any of a
range of domains (cognition, mobility, self-care, getting
along, life activities, or participation) or as the sum of
diﬃculties, impairment, and decreased productivity in
daily activities (93,94); HRQoL refers to the overall
eﬀect of illness and its therapy on the perception of
the ability to live a useful and fulﬁlling life, including
physical and mental components, general health per-
ception, and level of performance/participation in dif-
ferent roles (95,96). Restoring the ability to function
and improving quality of life are among the main
objectives of acute migraine treatment (97,98), and
the global impact of migraine can be measured by con-
sidering functional disability and quality of life.
However, it is important that the instruments employed
are appropriate for assessing the global eﬀect of treat-
ment on subjects’ quality of performance in diﬀerent
roles and daily activities and sense of wellbeing.
Based on previous recommendations in IHS Guidelines
(2,3), an NINDS-CDE recommendation as supplemental
evaluation instrument (54), and continuing use in trials of
acute treatment of migraine, the Functional Impairment
Scale (FIS) and the Migraine Physical Function Impact
Diary (MPFID) are recommended instruments for assess-
ing functional disability (54). A simple numerical scale
may be used to evaluate HRQoL, and of the global
impact assessment tools used in clinical trials of acute
treatment (88,99,100), only the 24-hour MSQoL and
Minor Symptoms Evaluation Proﬁle (a self-administered,
24-item instrument that uses a VAS to record perceived
symptoms of migraine) are well suited for assessing the
impact of acute treatment (101,102).
1.3.4.12. Associated symptoms – nausea and vomiting
Recommendation:
The presence or absence of nausea should be rec-
orded at the time trial treatment is administered and
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at the time of assessment of the primary eﬃcacy out-
come (e.g. 2 hours).
Comments:
Nausea and vomiting are important associated
symptoms of migraine, and acute migraine treatments
should demonstrate eﬃcacy against these symptoms.
Nausea and vomiting can also complicate treatment
when they occur as AEs, and therefore these variables
should be recorded for at least 24 hours after treatment.
When interpreting data about nausea or vomiting,
investigators should consider that they can be attributed
to (a) treatment eﬃcacy eﬀects; (b) treatment-induced
adverse eﬀects (i.e. treatment-emergent nausea or vomit-
ing); and (c) use of rescue medication for nausea or
vomiting when applicable. Finally, it is important to
rate the severity of nausea in trials that include anti-
emetics, either alone or in combination with other treat-
ments. A simple 4-point categorical verbal/numerical
scale (e.g. 0¼ none, 1¼mild, 2¼moderate, or
3¼ severe) can and has been used (103–105).
1.3.4.13. Associated symptoms – photophobia
Recommendation:
The presence or absence of photophobia should be
recorded before treatment is administered and at
the time of assessment of the primary eﬃcacy outcome
(2 hours).
Comments:
Photophobia is very commonly associated with
migraine attacks and can be disabling. Similar to
nausea and phonophobia, the eﬀect of an acute treat-
ment of migraine on photophobia should be evaluated
in migraine clinical trials. A simple assessment such as
presence or absence of photophobia is practical,
although verbal scales of severity can be used (e.g. a
4-point scale where 0¼ none, 1¼mild, 2¼moderate,
and 3¼ severe) (105). The presence or absence of
photophobia should also be recorded at 4, 8, 12, 24,
and 48 hours post-dose.
1.3.4.14. Associated symptoms – phonophobia
Recommendation:
The presence or absence of phonophobia should be
recorded before treatment is administered and at the
time of assessment of the primary eﬃcacy outcome
(e.g. 2 hours).
Comments:
Migraine-associated phonophobia can be disabling.
Similar to nausea and phonophobia, the eﬀect of an
acute migraine treatment on photophobia should be
evaluated in clinical trials. A simple assessment, such
as presence or absence of phonophobia, is practical
although verbal rating scales of severity can also be
used (e.g. a 4-point scale where 0¼ none, 1¼mild,
2¼moderate, and 3¼ severe) (105). The presence or
absence of phonophobia should also be recorded at 4,
8, 12, 24, and 48 hours after treatment.
1.3.4.15. Time between onset of headache and intake of
treatment
Recommendation:
Both timings should be recorded.
Comments:
The time interval between the onset of headache and
the use of an acute treatment is important for trials
investigating the eﬃcacy of early intervention (refer to
Section 2.2 for information about early intervention).
1.3.4.16. Treatment preference
Recommendation:
Subjects’ acute treatment preference is a useful
exploratory and hypothesis-generating global assess-
ment method (20,106–108) that is best suited for cross-
over trials.
Comments:
Treatment preference is a subjective assessment that
considers treatment beneﬁts and tolerability factors
(109). It can be used to compare a new acute treatment
with subjects’ usual treatment prior to the trial or, in a
crossover trial, preference among treatments (20). Past
clinical trials have used a questionnaire with preference
scores graded from 0 to 5 (110,111). Reported preferences
in clinical trials of acute migraine treatments have been
diﬃcult to interpret because of the heterogeneity in sub-
jects’ assessment of the balance between beneﬁts and tol-
erability issues; some patients prefer a more eﬀective drug
or dose at the expense of more AEs, if they are relatively
transient and mild, but others are willing to sacriﬁce a
minimal amount of eﬃcacy for a better tolerability proﬁle.
1.3.4.17. Blinding assessment
Recommendation:
It is important to determine how well a clinical trial
is blinded.
Comments:
The quality of blinding can be assessed using ques-
tionnaires. Indexes are available for the analysis of
results (e.g. James’ Index or Bang Index (112,113)),
though they are not totally free from bias (114).
1.3.4.18. Treatment of relapse
Recommendation:
The eﬃcacy of treatment for headache relapse
should be measured by the percentage of subjects
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with pain freedom 2 hours after the administration of
treatment for headache relapse.
Comments:
Relapse of headache pain of any intensity can be
treated with active treatment or placebo in a rando-
mised, double-blind clinical trial. Participants should
be re-randomized to active treatment or placebo for
the second dose. Measured by the pain relief endpoint,
the eﬃcacy of certain acute medications (e.g. oral trip-
tans) is similar whether the primary or the relapsing
headache is treated (34,78).
1.3.5. Adverse events
Recommendations:
1.3.5.1. Adverse events that occur during a clinical
trial should be recorded contemporaneously in the trial
diary.
1.3.5.2. Spontaneous real-time or synchronous
reporting of AEs is recommended and should be sup-
plemented by responses to open questions when
appropriate.
1.3.5.3. At a minimum, any subject experiencing an
AE in a clinical trial of an acute migraine treatment
should record event severity (mild, moderate, severe);
event seriousness (serious, non-serious); time of onset;
and time of resolution, as recommended by the
International Conference on Harmonisation’s
Guideline for good clinical practice (59).
Comments:
Adverse events that occur during a clinical trial are
not necessarily related to the acute treatment being
evaluated (115), and investigators should determine
whether any AEs are believed to be treatment-related.
Therefore, AEs should be recorded openly (i.e. spon-
taneously), without a priori biases (to detect any unex-
pected eﬀects), and within 24 hours of intake of acute
treatment (to mitigate problems of recall). The record-
ing of AEs should also adhere to the nomenclature and
hierarchy of theMedical dictionary for regulatory activ-
ities. Reports of AEs should include, at minimum, the
following for each treatment arm: Subjects with one or
more AE; subjects with any serious AE and details of
each serious AE, including causation; subjects who
withdrew because of AEs; subjects with individual,
pre-speciﬁed AEs based on a priori knowledge, if any,
of treatment or class tolerability proﬁles; severity of
speciﬁc AEs; and a detailed table of individual AEs.
Detailed tabulation of all AEs by organ system is rec-
ommended over a listing of only AEs occurring in a
pre-speciﬁed percentage of subjects (commonly 3–5%
or greater) or with a frequency that signiﬁcantly diﬀers
from another treatment arm. Finally, it is worth noting
that many regulatory authorities require additional
details of trial-related AEs beyond those aforemen-
tioned (59,116,117). Commonly used tools for analys-
ing AEs include the chi-square test and Fisher’s
exact test.
1.4. Statistics
1.4.1. Hierarchy of endpoints. The following hierarchy of
endpoints should be adopted for trials investigating the
eﬃcacy, tolerability, and safety of interventions for the
acute treatment of migraine.
Co-primary endpoints
. Pain-free after 2 hours
. Freedom from the most bothersome symptom at 2
hours
Secondary endpoints
. Supporting the primary endpoints
 Headache relief at 2 hours
 Sustained pain-free to 24 hours
 Total freedom from migraine
 Freedom from nausea and vomiting, photopho-
bia, or phonophobia
 Time to pain freedom
. All other endpoints (i.e. tertiary or exploratory
endpoints)
 Intensity of headache
 Headache relapse
 Time to meaningful relief
 Time to pain freedom
 Rescue medication
 Global evaluation
 Global impact (disability and HRQoL)
 Time between headache onset and treatment intake
 Preference to treatment
 Blinding assessment
 Treatment of recurrence
The recommended co-primary eﬃcacy measures for
single-attack trials are the proportion of subjects who
are pain-free within 2 hours of treatment and the pro-
portion of subjects who are free from the MBS within 2
hours of treatment. Inferences regarding diﬀerences can
be assessed using standard statistical methods, such as
the chi-square test or Fisher’s exact test, assuming there
are no baseline imbalances or known potential con-
founders to account for by Cochran-Mantel-Haenszel.
If a baseline imbalance exists between the two groups
on any covariates, then analysis may be performed
using logistic regression, with subject status as pain-
free within 2 hours as a binary outcome of interest
(yes, no) and treatment assignment as a primary pre-
dictor with inclusion of other pre-speciﬁed covariates
identiﬁed as imbalanced or confounders at baseline.
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To properly calculate a sample size, investigators
need to take the following four steps, at a minimum:
estimate placebo response rates for the primary out-
come measure, based on well-founded assumptions
and meta-analyses (118); deﬁne a clinically relevant dif-
ference between active and placebo response rates for
the primary outcome measure; establish the a priori
statistical errors (a- and ß); and determine an accept-
able trial power (1-ß) (119). In addition, the appropri-
ateness of an adjustment for multiple comparisons must
be considered in trials with more than one primary end-
point. Investigators do not have to limit these adjust-
ments to Bonferroni corrections, as there are various
other alternatives available, notably the hierarchical or
gatekeeper approach (120,121). Adjustment for mul-
tiple comparisons may not be necessary for secondary
and tertiary endpoints. The required sample size may be
much larger if the goal of the trial is to establish non-
inferiority or equivalence (122). Investigators need to
pre-specify acceptable limits for such considerations.
Standard statistical methods can also be used for
analysis of assessment measures in crossover and par-
allel-group trials. In addition to formal hypothesis test-
ing and reporting of p-values, CIs for diﬀerences
between an active treatment and placebo and between
two active treatments (123) are strongly recommended
to inform readers more fully of the meaning of the
results of the trial (124,125). A statement that two
drugs are equally eﬀective without giving CIs is
unacceptable. Time to event (pain-free) analyses (126)
or time to meaningful relief analyses can be performed
using Kaplan-Meier survival curves or Cox propor-
tional hazard regression methods to compare the
onset of action of two active treatments. Trials that
collect data from multiple attacks within a subject or
collect data at multiple time points may need to use a
repeated measures or generalized estimating equations
approach.
The statistical analysis plan needs to specify hand-
ling of missing data, with proper justiﬁcation behind
the choice of approach(es) for imputation.
Investigators should refer to the guidelines of the
agency or agencies funding the trial for information
on how to handle missing data.
Trials collecting intra-individual data at multiple
time points may beneﬁt from using a slope analysis,
which does not require imputation for missing data.
With this method, slope for each subject can be esti-
mated using data collected over time by ﬁtting a regres-
sion line. The slope estimates then become the outcome
of interest and allow the use of available data without
the need for any imputation, provided that at least one
post-baseline data point is available; they can be sum-
marized as mean (standard deviation), and 95% CIs
can be reported. For randomized controlled trials,
slope estimates between treatment arms can be com-
pared using a 2-sample t-test or a Wilcoxon rank sum
test. If a baseline imbalance exists between treatment
groups on any covariates, then a regression analysis
may be performed.
2. Special issues
2.1. Migraine with aura
Many people who have migraine without aura also
have attacks of migraine with aura (7). Both attack
types have, in most cases, similar headache features
and associated symptoms, and they may share the
same basic pain mechanisms. So far, no treatment has
been shown to be eﬀective when administered in the
aura phase, either for reducing the duration of the
aura or preventing the subsequent headache; in separ-
ate assessments of acute treatment given during the
aura phase, sumatriptan 6mg SC and eletriptan 40mg
oral tablets had no eﬀect on the aura or the headache
(127,128).
The main challenge in clinical trials focused on sub-
jects who have migraine with aura is diagnostic accur-
acy. The current ICHD classiﬁcation (10) recognizes the
main type, migraine with typical aura (group 1.2.1), as
well as variants for typical aura followed by migraine
headache, typical aura followed by non-migraine head-
ache, and aura not followed by headache. Since most
acute treatment trials are carried out in mixed popula-
tions – subjects who have migraine with aura, subjects
who have migraine without aura, and subjects who have
attacks of both migraine types – investigators cannot
determine whether both types of attacks occurring in
the same subject have similar or diﬀerent responses to
treatment unless each attack is separately classiﬁed as
migraine with aura or migraine without aura.
Therefore, a detailed recording of each aura symptom
and the total duration of the aura is mandatory, and
these should be based on uniform requirements (129).
To improve accuracy and ensure that response to
migraine-associated aura is being evaluated, diagnostic
and treatment diaries capable of recording speciﬁc aura
symptoms and duration of aura should be used (130).
With these specialized instruments, an observation of
blurred vision or visual snow (131), which might be
mistaken for aura with a standard diary, would not be
enough to classify an attack as migraine with aura (132).
Note that in trials designed to assess treatment of the
aura phase, detailed instruction about the proper use of
diaries is mandatory.
Additional challenges hindering clinical trials for the
acute treatment of aura include the low incidence and
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relatively short duration of aura, together with the high
inter-individual variability of aura characteristics
(133,134). The adoption of alternative trial designs
may help to overcome these challenges and the conse-
quent lack of speciﬁc treatments for migraine-asso-
ciated aura. As a ﬁrst step, the trial protocol should
clearly state if the objective is to abort or reduce the
length of the aura or to reduce or eliminate the head-
ache, as these are distinct outcomes that most likely
have diﬀerent neurobiologies. It should also specify
that participants have a history of at least one aura
or attack of migraine with aura per month. In trials
where the expected eﬀect of treatment is to prevent
the headache phase, the primary eﬃcacy endpoint
should be the number of headaches following the
aura, with pain freedom after 2 hours a secondary eﬃ-
cacy measure. When the focus is on headache preven-
tion in migraine with aura, a feasible compromise can
be aura followed by headache in at least 80% of the
attacks. In trials where aura is the event of interest,
the primary eﬃcacy measure should be the duration
of the aura.
2.2. Early intervention
To facilitate migraine diagnosis and assess whether
acute treatment will be eﬀective when headache inten-
sity is moderate or severe, subjects in clinical trials are
often required to wait until headache pain is of at least
moderate intensity before they treat an attack (45). This
is not how migraine attacks are treated in clinical prac-
tice, where early intervention may be the most eﬀective
acute treatment strategy. With many oral triptans, for
example, early intervention has been shown to lead to a
higher percentage of pain-free responses at 2 hours
after treatment than traditional administration (i.e.
when headache intensity is moderate or severe) (135):
57% versus 43% for zolmitriptan 2.5mg (136), 68%
versus 47% for eletriptan (137), 53% versus 38% for
almotriptan 12.5mg (43), 58% versus 32% for suma-
triptan 100mg (138,139), and 66% versus 44% for riza-
triptan 10mg (140,141)). Early treatment while pain is
mild has been associated with higher pain free rates for
non-triptan acute treatments as well.
2.2.1. Design. Early intervention trials were once char-
acterized by wide variations in methodology and design
and important diﬀerences in the deﬁnition of an early
intervention. As the time of treatment (how soon after
onset treatment is taken) and headache intensity (treat-
ment is taken when pain is mild) are not necessarily
interchangeable (142), early intervention should be
deﬁned as the administration of treatment when pain
intensity is mild and within 1 hour of headache onset.
By this deﬁnition, individuals with headaches predom-
inantly occurring at night or on waking in the morning,
as well as those who experience more than one head-
ache type and who are not able to diﬀerentiate migraine
from other headaches, should be excluded from early
intervention trials.
The speciﬁcs of an early intervention design depend
on the purpose of the trial. If its objective is to show that
a drug is more eﬀective than placebo when treating early
in the mild phase (138), then a traditional parallel-group
comparison or crossover design can be used (refer to
Section 1.2.3 for more information about design
types). However, if its objective is to show that early
treatment (when pain is mild) is more eﬀective than
late treatment (when pain is moderate/severe), the the-
oretically ideal design would be a multiple crossover trial
in which the same subject treats four attacks (early inter-
vention with placebo, early intervention with active, late
intervention with placebo, and late intervention with
active) in randomized order. Because a trial using this
design would be complex, an acceptable option would be
a design used by Goadsby et al. (43), in which subjects in
four parallel arms (early intervention with placebo, early
intervention with active, late intervention with placebo,
and late intervention with active) treat a single attack.
Another suitable alternative would utilize a two-arm
parallel design, with treatment arms allocated to early
intervention and late intervention, and subjects treating
two attacks (one with placebo and one with active) in a
randomized order.
2.2.2. Endpoints. The primary eﬃcacy endpoint in early
intervention trials should be pain-free at 2 hours after
treatment. However, as the aim of early intervention
trials is also to evaluate eﬃcacy on pain progression,
sustained pain-free to 24 or 48 hours (refer to
Section 1.3.4.2) should be used as a co-primary end-
point. The number of protocol violators (subjects
assigned to treat mild headache who treat moderate-
severe and vice versa) in early intervention trials can
be substantial (43). As protocol violators, these subjects
can be excluded from the ITT analysis, but there is a
risk that analysis of the smaller sample will not be suf-
ﬁciently powered to detect treatment eﬀects. An accept-
able alternative is to reassign these subjects to their
actual treatment groups, as long as the re-allocation is
done before the blind is broken.
2.3. Menstrual migraine
In menstruating females, the peak incidence of migraine
occurs in the interval beginning 2 days before and
extending through the ﬁrst few days of menstruation
(143). The Appendix of ICHD-3 provides criteria for
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pure menstrual migraine and menstrually-related
migraine. For both disorders, attacks occur on days
2 toþ 3 of menstruation in at least two out of three
menstrual cycles (6). For pure menstrual migraine,
attacks occur at no other time of the month, while in
menstrually-related migraine attacks may occur at
other times (6). Pure menstrual migraine is less
common than menstrually-related migraine; in one
study, only 7% of females had pure menstrual migraine
while 34.5% had menstrually-related migraine (144).
Migraine attacks occurring in association with men-
struation are generally noted to be severe, of long dur-
ation, and associated with higher relapse rates
(145,146). Acute treatment trials might therefore inves-
tigate the eﬃcacy of a new therapy by comparing its
rate of relapse with those of standard treatments in
subjects with menstrually-related migraine, pure men-
strual migraine, or both conditions. If the eﬀect of an
acute treatment on pure menstrual migraine is to be
investigated, accurate diagnosis is essential; it is recom-
mended that subjects record migraine attacks and men-
strual periods prospectively in a headache dairy for two
to three cycles before entering the trial and that inves-
tigators apply the strict deﬁnition provided above to
distinguish them from subjects with menstrually-related
migraine. Three months of prospective diary informa-
tion may be needed to be certain of the diagnosis (147).
If the aim is to assess the eﬀect of a treatment on men-
strually-related migraine attacks, it is recommended
(but not mandatory) that randomized subjects report
menstruation in the headache diary, treating at least
one menstrually-related attack with the test treatment.
In either population, subjects need careful instruction
on allowable limits for the temporal relationship
between the migraine attack and the ﬁrst day of men-
struation. The primary eﬃcacy measure should be the
percentage of subjects who achieve freedom from pain
at 2 hours after treatment (refer to Section 1.3.2), but in
subjects experiencing these often long-lasting attacks
with a high risk of recurrence, sustained pain-free
(refer to Section 1.3.4.2.) is also an important measure.
2.4. Children and adolescents
Migraine attacks are usually short-lasting in children
and adolescents, and the placebo response tends to be
high. The IHS is developing a separate set of recom-
mendations for clinical trials of acute treatment of
migraine attacks in children and adolescents.
2.5. Recruitment
Investigators should recruit widely from the population
expected to use the acute treatment being evaluated. For
example, all individuals being treated for migraine at
speciality clinics and primary care facilities should be con-
sidered for enrolment in clinical trials, as long as they
meet eligibility criteria. Recruitment for phase II clinical
trials may be more readily conducted in speciality clinics
(where appropriate safety resources exist), whereas trials
investigating generic or OTC drugs should try to recruit
subjects from pharmacies and primary care facilities, as
well as via newspaper advertisements. The inclusion of
people who habitually participate in migraine clinical
trials is discouraged. It is also recommended that investi-
gators establish a database of the number of migraine
trials of any kind in which a particular subject has parti-
cipated in the 2 years preceding a clinical trial. Subject
participation in earlier trials should be recorded and pre-
sented in the publication. Recruitment eﬀorts and strate-
gies should also be disclosed in the publication.
2.6. Publication
Publication of trial results is necessary and should include
all primary and secondary eﬃcacy endpoints and all
safety data, whether positive or negative. Before any
trial-related activities are initiated, a Steering
Committee (refer to Section 2.9 for details) should
agree on timelines for publication and, if possible, include
them in the protocol; a Publication Committee may also
be formed. At the initiation of the trial or at the end of
recruitment, a design paper with baseline data may be
published. Authorship of trial-related publications
should be based on the criteria of the International
Committee of Medical Journal Editors (148).
2.7. Conflicts of interest
To maintain the credibility of a trial, authors must
declare their conﬂicts of interest. A conﬂict of interest
exists whenever professional judgment concerning a pri-
mary interest (e.g. subject wellbeing or the validity of
research) may be inﬂuenced by a secondary interest
(e.g. ﬁnancial relationship to a trial sponsor). Financial
relationships that represent potential conﬂicts of interest
include employment, consultancies, research grants, fees
and honoraria, patents, royalties, stock or share owner-
ship, and paid expert testimony. Investigators should
avoid agreements with sponsors, both for-proﬁt and
non-proﬁt, that restrict access to trial data, limit its ana-
lysis and interpretation, or interfere with the independ-
ent preparation and publication of manuscripts. Note
that conﬂicts of interest extend to an investigator’s
immediate family (partner and children).
2.8. Independent data safety monitoring board
An independent data safety monitoring board and prede-
ﬁned stopping rules for futility or safety are recommended
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for phase III trials. Independent interim analysis by the
data safety monitoring board should be considered for
assessment of the pre-deﬁned stopping rules.
2.9. Steering committee
For phase III trials sponsored by industry, the formation
of a Steering Committee comprised of academics, statis-
ticians, and (if appropriate) company representatives is
recommended. For investigator-initiated trials (i.e.
developed and sponsored by independent investigators
or academia), a Steering Committee is not necessary.
Whether or not a committee is formed, investigators
and sponsors are responsible for all aspects of a clinical
trial, including conception; design; operational execu-
tion; data handling; data analysis and interpretation;
subsequent reporting and publication; and compliance
with all local laws and regulations.
2.10 Trial registration
Prior to the initiation, any trial should be pre-registered
in a register acknowledged by regulatory authorities,
such as clinicaltrials.gov, clinicaltrialsregister.eu, or a
similar regional or national oﬃcial database.
2.10. Post-approval registries
The IHS recommends post-approval product registries
(i.e. prospective open-label observational studies) to
evaluate the use of newly approved acute treatments
in clinical practice. Registries generate real-world data
on long-term eﬃcacy, tolerability, and safety. They also
measure compliance and adherence. Registries for
acute migraine treatments may also include individuals
with relevant coexistent and comorbid diseases (e.g.
chronic pain syndromes, cardiovascular disease) who
were excluded from clinical trials for acute migraine.
Section number Summary guidance
1.1 Subject selection
1.1.1 Migraine definition Use ICHD diagnostic criteria
1.1.2 Other primary headaches Permitted if infrequent and clearly recognized by the patient
1.1.3 Secondary headaches Not permitted
1.1.4 Frequency of attacks 2–8 migraine attacks; 1 per month for other headache types (including non-
target)
1.1.5 Duration of migraine  1 year
1.1.6 Age at onset < 50 years
1.1.7 Age at entry 18–65 years
1.1.8 Sex Females and males
1.1.9 Concomitant drug use See text
1.2 Trial design
1.2.1 Blinding Use double-blind
1.2.2 Placebo control Recommended
1.2.3 Design types Parallel-group and crossover
1.2.4 Randomization Recommended
1.2.5 Stratification Generally not necessary
1.2.6 Intention to treat Should be defined, see text
1.2.8 Route of administration Oral route is preferable if appropriate for the PK profile
1.2.9 Timing of administration Should be prospectively defined in the protocol
1.2.10 Number of attacks treated One, generally the first, see text
1.2.11 Rescue medication Allowed any time after the first primary efficacy time point
1.2.12 Consistency of response Evaluate 4 attacks, with 1 treated with placebo
1.3 Evaluation of results
1.3.1 Attack report form (diary) An easy-to-use electronic diary that captures predefined endpoints
1.3.2 Primary endpoint Pain freedom at 2 hours
(continued)
3. Toolbox
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Clinical implications
. The Guidelines of the International Headache Society for controlled trials of acute treatment of migraine
attacks in adults: Fourth edition provides new information that will aﬀect the design, conduct, and reporting
of clinical trials in migraine.
. The current edition supersedes the existing Guidelines and should be put to immediate use.
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Section number Summary guidance
1.3.3 Co-primary endpoint Absence of the most bothersome associated symptom at 2 hours
1.3.4 Secondary endpoints
1.3.4.1 Relapse Secondary endpoint, see text
1.3.4.2 Sustained pain-free Secondary endpoint, see text
1.3.4.3 Total freedom from migraine Secondary endpoint, see text
1.3.4.4 Headache intensity Secondary endpoint, on a 4-point verbal rating scale
1.3.4.5 Headache relief Secondary endpoint, see text
1.3.4.6 Time to meaningful relief Secondary endpoint, see text
1.3.4.7 Time to pain freedom Secondary endpoint, measured with a survival analysis of pain freedom at time
points before 2 hours
1.3.4.8 Duration of attacks Not recommended
1.3.4.9 Rescue medication Secondary endpoint, see text
1.3.4.10 Global evaluation Secondary endpoint, see text
1.3.4.11 Global impact (functional dis-
ability and quality of life)
Secondary endpoint, on a 4-point verbal rating scale
1.3.4.12 Associated symptoms —
nausea and vomiting
Secondary endpoint, recorded at the time treatment is administered and at the
time of assessment of the primary endpoint
1.3.4.13 Associated symptoms —
photophobia
Secondary endpoint, recorded at the time treatment is administered and at the
time of assessment of the primary endpoint
1.3.4.14 Associated symptoms —
phonophobia
Secondary endpoint, recorded at the time treatment is administered and at the
time of assessment of the primary endpoint
1.3.4.15 Time between headache onset
and treatment intake
Secondary outcome measure
1.3.4.16 Treatment preference Exploratory and hypothesis-generating global assessment method for crossover
trials
1.3.4.17 Blinding assessment Secondary outcome measure
1.3.4.18 Treatment of relapse Secondary outcome measure, see text
1.3.4.19 Adverse events Record and report all events, see text
1.4 Statistics
1.4.1 Hierarchy of endpoints Recommended for use in trial design, conduct, and reporting
ICHD, International Classification of Headache Disorders
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